Israel · Delayed Price · Currency is ILS · Price in ILA Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of ILS 18.65 million. The enterprise value is 684,492.
| Market Cap | 18.65M |
| Enterprise Value | 684,492 |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 1.86 billion shares outstanding. The number of shares has increased by 267.67% in one year.
| Current Share Class | 1.86B |
| Shares Outstanding | 1.86B |
| Shares Change (YoY) | +267.67% |
| Shares Change (QoQ) | +16.70% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 18.83% |
| Float | 1.85B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.70 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -876.22 |
Financial Efficiency
Return on equity (ROE) is -111.13% and return on invested capital (ROIC) is -22.15%.
| Return on Equity (ROE) | -111.13% |
| Return on Assets (ROA) | -20.31% |
| Return on Invested Capital (ROIC) | -22.15% |
| Return on Capital Employed (ROCE) | -63.68% |
| Weighted Average Cost of Capital (WACC) | 1.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -7.30M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.43% in the last 52 weeks. The beta is -0.54, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.54 |
| 52-Week Price Change | -71.43% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 1.60 |
| Relative Strength Index (RSI) | 40.99 |
| Average Volume (20 Days) | 373,275 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -175,767 |
| Operating Income | -23.49M |
| Pretax Income | -73.27M |
| Net Income | -72.97M |
| EBITDA | -23.36M |
| EBIT | -23.49M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 18.19 million in cash and 399,199 in debt, with a net cash position of 17.79 million or 0.01 per share.
| Cash & Cash Equivalents | 18.19M |
| Total Debt | 399,199 |
| Net Cash | 17.79M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 36.38M |
| Book Value Per Share | 0.02 |
| Working Capital | 14.32M |
Cash Flow
In the last 12 months, operating cash flow was -23.11 million and capital expenditures -11,916, giving a free cash flow of -23.12 million.
| Operating Cash Flow | -23.11M |
| Capital Expenditures | -11,916 |
| Depreciation & Amortization | 137,416 |
| Net Borrowing | -746,825 |
| Free Cash Flow | -23.12M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -267.67% |
| Shareholder Yield | -267.67% |
| Earnings Yield | -391.34% |
| FCF Yield | -124.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2019. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 6, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |